Investigation Launched by Pomerantz Law Firm for Omeros Corporation Investors

Investor Alert: Omeros Corporation Under Investigation

Omeros Corporation, a biopharmaceutical company known for its innovative therapies, is currently facing scrutiny as Pomerantz LLP initiates an investigation on behalf of the company's investors. This follows significant market reactions due to a recent announcement regarding their application for marketing authorization in Europe, specifically relating to their drug, narsoplimab.

On June 26, 2026, Omeros disclosed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) delivered a negative opinion on their marketing authorization application (MAA) for narsoplimab, aimed at treating a rare complication associated with hematopoietic stem cell transplants, known as thrombotic microangiopathy (TA-TMA). This decision was made after the company presented its case during an oral explanation meeting, alongside insights from international experts in related fields.

The market responded sharply to this news, with Omeros's share price plunging by approximately 19.12%, resulting in a closing price of $8.67 per share. Investors have begun to question whether the company and its leadership engaged in any form of securities fraud or engaged in questionable business practices that could have informed their decision-making process prior to this adverse announcement.

Pomerantz LLP, recognized as a leading firm specializing in corporate and securities class actions, is reaching out to affected investors for collective action. The firm has a history of advocating for the rights of securities fraud victims and has successfully recovered substantial damages for their clients over the years.

Founded over 85 years ago by Abram L. Pomerantz, the firm has developed a reputation for excellence in the legal field of corporate and securities law, often described as the leader in the class action domain. They believe that, through this investigation, they can shed light on the motivations and decisions taken by Omeros's executives that led to this troubling situation.

Investors who believe they have been harmed by this decrease in stock value are encouraged to contact the firm, either by reaching out to Danielle Peyton via email or telephone as provided in the investor alert notice, to discuss the possibility of joining the class action lawsuit.

As the situation develops, further insights into Omeros’s corporate governance and compliance with securities laws will be thoroughly examined. Investors are advised to stay informed about this ongoing investigation as more information becomes available. The outcome may have lasting implications not just for the company's stock price but for its operational integrity and the trust of its investor base.

In conclusion, as pharmaceutical companies navigate increasingly complex regulatory environments, it becomes crucial for investors to remain vigilant. Legal firms like Pomerantz are integral in advocating for shareholder interests and uncovering the truth behind corporate decisions.

For ongoing updates, stay connected with corporate news outlets and consider joining investor groups focused on this case.

If you believe you qualify as a class member in the Omeros Corporation case, or if you have questions regarding your investments, please feel free to reach out for more information. Your rights as an investor are at the forefront of this investigation, and it is essential to understand the protections available under securities law.